文献速递眼底病与葡萄膜炎

生物制剂治疗难治性活动性非感染性中间型葡萄膜炎、后葡萄膜炎或全葡萄膜炎的长期结局

Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
PubMed 文献 · Ophthalmology · 2019-09-06

这项回顾性纵向研究纳入2001至2016年在Moorfields眼科医院因糖皮质激素和二线免疫抑制剂治疗失败后接受生物制剂治疗的82例(156眼)活动性非感染性中间型、后或全葡萄膜炎患者,平均随访4.7±0.4年(724眼年)。结果显示87.2%的眼实现眼部炎症控制,泼尼松龙剂量从基线16.4±1.7 mg/天降至6个月时6.5±0.7 mg/天(P<0.0001),最佳矫正视力从基线0.5±0.1 logMAR改善至3个月时0.4±0.1 logMAR(P=0.008),23.7%的眼治疗失败。多因素校正后,阿达木单抗(对比英夫利西单抗)与较低的治療失败风险相关(OR 0.4,95%CI 0.2-0.9,P=0.03),而基线合并活动性系统性疾病与较高的失败风险相关(OR 3.2,95%CI 1.5-7.1,P=0.004)。

要点

  • 生物制剂治疗难治性活动性非感染性中间型、后或全葡萄膜炎,87.2%的眼实现炎症控制,23.7%的眼治疗失败。
  • 泼尼松龙平均剂量从基线16.4±1.7 mg/天降至6个月时6.5±0.7 mg/天(P<0.0001),并稳定至5年随访。
  • 阿达木单抗(对比英夫利西单抗)与较低的治療失败风险相关(OR 0.4,95%CI 0.2-0.9,P=0.03)。

核心结论

  • 整体上,糖皮质激素和二线免疫抑制剂治疗失败后接受生物制剂治疗的眼实现了满意的疾病控制(87.2%)、减少全身免疫抑制使用、视力稳定,且疾病复发风险为23.7%。
  • 多因素校正后,年龄较大、阿达木单抗治疗(对比英夫利西单抗)以及合并的系统性疾病处于非活动状态与较低的治療失败风险相关。

研究设计与样本

  • 回顾性纵向研究。
  • 纳入2001至2016年在Moorfields眼科医院治疗的82例患者(156眼),均为糖皮质激素和二线免疫抑制剂治疗失败后的活动性非感染性中间型葡萄膜炎、后葡萄膜炎或全葡萄膜炎,并接受生物制剂治疗。
  • 信息从所有患者的临床记录中收集。

主要发现

  • 患者平均随访4.7±0.4年(724眼年),所有患者基线时均表现为活动性葡萄膜炎,34例(41.5%)合并活动性系统性疾病。
  • 136眼(87.2%)实现眼部炎症控制;口服泼尼松龙平均剂量从基线16.4±1.7 mg/天降至6个月时6.5±0.7 mg/天(P<0.0001),并稳定至5年随访。
  • 最佳矫正视力从基线0.5±0.1 logMAR改善至3个月时0.4±0.1 logMAR(P=0.008),随访期间保持稳定。
  • 基线后42.3%的眼发生 flare,平均 flare 次数从1.8±0.1次/年降至0.6±0.1次/年(P<0.0001);首次 flare 中位时间为5.4年(95%CI 2.2-5.4年),5年生存率为58.7%。
  • 37眼(23.7%)治疗失败,5年生存率为68.0%,估计达到75%生存的时间为2.9年(95%CI 2.1-4.4年);阿达木单抗治疗与较低的治療失败风险相关(OR 0.4,95%CI 0.2-0.9,P=0.03),基线合并活动性系统性疾病与较高的失败风险相关(OR 3.2,95%CI 1.5-7.1,P=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine a large cohort of patients treated with biologic agents for active noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIPPU) and to compare their efficacy and long-term effect. DESIGN: Retrospective, longitudinal study. PARTICIPANTS: Eighty-two patients (156 eyes) with active NIPPU after failure of treatment with corticosteroids and a second-line immunosuppression drug and treated with biologic agents who were treated at Moorfields Eye Hospital between 2001 and 2016. METHODS: Information was gathered from the clinical notes of all patients. MAIN OUTCOME MEASURES: Time to first disease flare, rate of treatment failure, best-corrected visual acuity, and risk factors for treatment failure. RESULTS: Patients were followed on average for 4.7±0.4 years (724 eye-years). All patients demonstrated active uveitis at baseline, and 34 patients (41.5%) demonstrated a coexisting active systemic disease. Control of ocular inflammation was achieved in 136 eyes (87.2%). The average oral prednisolone dose at baseline was 16.4±1.7 mg/day, and by 6 months reduced to 6.5±0.7 mg/day (P < 0.0001), remaining stable for up to 5 years follow-up. Best-corrected visual acuity at baseline was 0.5±0.1 logarithm of the minimum angle of resolution (logMAR), improved to 0.4±0.1 logMAR (P = 0.008) at 3 months, and remained stable during follow-up. After baseline, 42.3% of eyes experienced flares, and the average number of flares reduced from 1.8±0.1 flares/year to 0.6±0.1 flares/year (P < 0.0001). Median time to first flare was 5.4 years (95% confidence interval [CI], 2.2-5.4 years) with a 5-year survival rate of 58.7%. Treatment failed in 37 eyes (23.7%), with a 5-year survival rate of 68.0% and an estimated time to 75% survival of 2.9 years (95% CI, 2.1-4.4 years). The risk for treatment failure was lower when treatment used adalimumab (odds ratio, 0.4; 95% CI, 0.2-0.9; P = 0.03) but was greater when systemic disease also was active at baseline (odds ratio, 3.2; 95% CI, 1.5-7.1; P = 0.004). CONCLUSIONS: Overall, eyes treated with biologic agents after failure of treatment with corticosteroids and a second-line immunosuppression drug experienced satisfactory disease control (87.2%), reduced use of systemic immunosuppression, stable visual acuity, and a 23.7% risk of disease relapse. After multivariate adjustment, older age, treatment with adalimumab (versus infliximab), and inactive concomitant systemic disease were associated with a lower risk of treatment failure.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Al-Janabi A, El Nokrashy A, Sharief L, et al. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2019. PMID: 31607412. doi:10.1016/j.ophtha.2019.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。